Keto research is moving past the scale. A pilot study in Nutrients looked at 25 obese patients with hepatic fibrosis and found that 8 weeks of very low energy ketogenic therapy, or VLEKT, altered their serum metabolic profile in ways that may matter for how fatty liver disease is managed.
The team at the National Institute of Gastroenterology IRCCS S. de Bellis in Castellana Grotte, Bari, with collaborators at Politecnico di Bari, analyzed 50 serum samples, taken at baseline and again after treatment, using 1D 1H CPMG NMR spectroscopy. That setup gives a broad metabolic fingerprint of the blood, the kind of readout that can show whether fuel use, lipid handling and other pathways are shifting after strict carbohydrate restriction and energy reduction. In plain terms, it helps answer a question keto fans have long cared about: is the body just dropping weight, or is it changing the way it runs?
What makes this study stand out is its focus on fibrosis. In fatty liver disease, fibrosis is the feature clinicians watch most closely because it helps drive prognosis and treatment intensity. Noninvasive tools such as FibroScan, FIB-4 and liver-stiffness measurement are already used to stratify risk, so asking whether fibrosis changes the serum response to VLEKT is a logical next step. If the metabolic signature looks different in patients with fibrosis, that could eventually help personalize ketogenic therapy for people who are dealing with obesity plus liver disease, not obesity alone.
The study is exploratory, and that is exactly why it matters. Small pilot work does not settle the debate, but it can show which metabolic pathways are worth tracking in larger trials and whether a subgroup behaves differently from the wider obesity population. This paper also fits a broader Italian research program built around very-low-energy ketogenic therapy, including recent work on extracellular vesicles, liver-cell biology and an 80-woman prospective study in MASLD. The field is also sharpening its language: a 2025 review described VLEKT as an updated term meant to make obesity trials around ketogenic diets more consistent and easier to compare.
That is the real takeaway for the keto community. The new serum NMR study does not prove that fibrosis changes who benefits most, but it pushes the conversation toward organ health, metabolic flexibility and tailored therapy. In a space that has often been reduced to weight-loss headlines, this is a more precise and more useful question, and it is one worth watching closely.
Every story on Keto Diet Magazine is assembled by an automated editorial system that works from verified research, official records, and credible reporting, then clears automated accuracy and moderation checks before it goes live. The standards that system follows are set and overseen by the people who run the publication. Read our full editorial policy.
Know something we missed? Have a correction or additional information?
Submit a Tip
